Comparison between Olanzapine and Haloperidol on Procedural Learning and the Relationship with Striatal D2 Receptor Occupancy in Schizophrenia

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 16, Issue 1, 2004, Pages 47-56

  Paquet, F ^b   Soucy, J P ^b   Stip, E ^b   Levesque M ^b   Elie, A ^b   Bedard M A ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; OLANZAPINE;

ADULT; ANALYTIC METHOD; ARTICLE; CLINICAL TRIAL; COMPUTED VISUAL TRACKING TASK; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RECEPTOR BLOCKING; HUMAN; LEARNING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROCEDURAL LEARNING; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TASK PERFORMANCE;

EID: 1242329937     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.16.1.47     Document Type: Article

References (50)

1. Cohen NJ, Squire LR: Preserved learning and retention of pattern-analyzing skill in amnesia: Dissociation of knowing how and knowing that. Science 1980; 210:207-210
2. Harrington DL, Haaland KY, Yeo RA, et al: Procedural memory in Parkinson's disease: Impaired motor but not visuoperceptual learning. J Clin Exp Neuropsychol 1990; 12:323-339
3. Knopman D, Nissen MJ: Procedural learning is impaired in Huntington's disease: Evidence from the serial reaction time task. Neuropsychologia 1991; 29:245-254
4. Saint-Cyr JA, Taylor AE, Lang AE: Procedural learning and neostriatal dysfunction in man. Brain 1988; 111:941-959
5. Grafton ST, Mazziotta JC, Presty S, et al: Functional anatomy of human procedural learning determined with regional cerebral blood flow and PET. J Neurosci 1992; 12:2542-2548
6. Jueptner M, Frith CD, Brooks DJ, et al: Anatomy of motor learning. II. Subcortical structures and learning by trial and error. J Neurophysiol 1997; 77:1325-1337
7. Goldberg TE, Saint-Cyr JA, Weinberger DR: Assessment of procedural learning and problem solving by tower of Hanoi type tasks. J Neuropsychiatr Clin Neurosci 1990; 2:165-173
8. Granholm E, Bartzokis G, Asarnow RF, et al: Preliminary association between motor procedural learning, basal ganglia T2 relaxation times and tardive dyskinesia in schizophrenia. Psychiatr Res Neuroimag 1993; 50:33-44
9. Gras-Vincedon A, Danion JM, Grangé D et al: Explicit memory, repetition priming and cognitive skill learning in schizophrenia. Schizophr Res 1994; 13:117-126
10. Green MF, Kern RS, Williams O, et al: Procedural learning in schizophrenia: Evidence from striatal reaction time. Cognit Neuropsychiatry 1997; 2:123-134
11. Michel L, Danion JM, Grang D, et al: Cognitive skill learning and schizophrenia: Implications for cognitive remediation. Neuropsychol 1998; 12:590-599
12. Schwartz BL, Rosse RB, Veazey C, et al: Impaired motor skill learning in schizophrenia: Implications for corticostriatal dysfunction. Biol Psychiatry 1996; 39:241-248
13. Bédard MA, Schérer H, Delorimier J, et al: Differential effect of D2 and D4-blocking neuroleptics on the procedural learning of schizophrenic patients. Can J Psychiatry 1996; 41:21S-24S
14. Bédard MA, Schérer H, Stip E, et al: Procedural learning in schizophrenia: Further consideration on the deleterious effect of neuroleptics. Brain Cogn 2000; 43:31-39
15. Clare L, McKenna PJ, Mortimer AM, et al: Memory in schizophrenia: What is impaired and what is preserved? Neuropsychologia 1993; 31:1225-1241
16. Danion JM, Peretti S, Grange D, et al: Effects of chlorpromazine and lorazepam on explicit memory, repetition priming and cognitive skill learning in healthy volunteers. Psychopharmacology 1992; 108:345-351
17. Peretti CS, Danion JM, Kauffman-Muller F, et al: Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers. Psychopharmacology (Berl) 1997; 131:329-338
18. Chiodo LA, Bunney BS: Typical and atypical neuroleptics: Differential effect of chronic administration on the activity of A9 and A10 midbrain dopamine neurons. J Neurosci 1983; 3:1607-1619
19. 2 dopamine receptor occupancy of risperidone and its relationship to extra-pyramidal symptoms: A PET study. Life Sci 1995; 57:103-107
20. Kapur S: A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Mol Psychiatry 1998; 3:135-140
21. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544
22. Miller CH, Mohr F, Umbricht D, et al: The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics. J Clin Psychiatry 1998; 59:69-75
23. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1998; 13:261-276
24. Chouinard G, Chouinard AR: Extrapyramidal symptom rating scale (ESRS), 1979
25. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
26. Lobbezoo F, Soucy JP, Montplaisir JY, et al: Striatal D2 receptor binding in sleep bruxism: A controlled study with iodine-123-iodobenzamide and single-photon-emission computed tomography. J Dental Res 1996; 75:1804-1810
27. Willingham DB, Hollier J, Joseph J: A Macintosh analogue of the rotary pursuit task. Behav Res Methods Instrum Comput 1995 27:491-495
28. Kumari V, Coor PJ, Mulligan OF, et al: Effects of acute administration of d-amphetamine and haloperidol on procedural learning in man. Psychopharmacology 1997 129:271-276
29. Jog MS, Kubota Y, Connolly CI, et al: Building neural representation of habits. Science 1999; 286:1745-1749
30. Schérer H, Paquet F, Stip E, et al: Mild procedural learning disturbances in neuroleptic-naive patients with schizophrenia. J Neuropsychiatry Clin Ceurosci 2002 (in press).
31. Kapur S, Zipursky RB, Remington G, et al: 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation. Am J Psychiatry 1998; 155:921-928
32. Kapur S, Zipursky RB, Remington G: Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia. Am J Psychiatry 1999; 156:286-293
33. Bymaster FP, Calligaro DO, Falcone JF, et al: Radioreceptor binding profile of atypical antipsychotic olanzapine. Neuropsychopharmacol 1996; 14:87-96
34. 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology 1996; 124:148-153
35. Tauscher J, Küfferle B, Asenbaum S, et al: In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology 1999; 141:175-181
36. Dresel S, Mager T, Rossmuller B, et al: In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine 123 iodobenzamine single-photon emission tomography study. Eur J Nucl Med 1999; 26:862-868
37. Lavalaye J, Linszen DH, Booij J, et al: Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. Psychiatry Res 1999; 92:33-44
38. Meisenzahl EM, Dresel S, Frodl T, et al: D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamine SPECT study. J Psychopharmacol 2000; 14:364-370
39. Readler TJ, Knable MB, Lafargue T, et al: In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine. Psychiatry Res 1999; 90:81-90
40. Kapur, S, Seeman P: Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001; 158:360-369
41. Tauscher J, Kapur S: Choosing the right dose of antipsychotics in schizophrenia: Lessons from neuroimaging studies. CNS Drugs 2001; 15:671-678
42. Kapur S, Zipursky R, Roy P, et al: The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: A PET study. Psychopharmacology 1997; 131:148-152
43. Michal P, Lysikova M, El-Fakahany EE, et al: Clozapine interaction with M2 and M4 subtypes of muscarinic receptors. Eur J Pharmacol 1999; 376:119-125
44. Meltzer HY, Matsubara S, Lee JC: The ratio of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25:390-392
45. Meltzer HY, Matsubara S, Lee JC: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin pKi values. J Pharmacol Exp Ther 1989; 251:238-251
46. 2 dopamine receptor occupancy in the living human brain: A PET study with risperidone. Psychopharmacology 1993; 110:265-272
47. 2 receptor effects of antipsychotics: Bridging basic and clinical findings using PET. J Clin Psychiatry 1999; 60:15-19
48. Herrick-Davis K, Grinde E, Teitler M: Inverse agonist activity of atypical antipsychotic drugs at human 5-Hydroxytryptamine2C receptors. J Pharmacol Exp Ther 2000; 295:226-232
49. Meltzer HY: New insights into schizophrenia through atypical antipsychotic drugs. Neuropsychopharmacology 1998; 1:193-196
50. Seeger TF, Seymour PA, Schmidt AW, et al: Ziprazidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275:101-133